1. Home
  2. LMB vs COLL Comparison

LMB vs COLL Comparison

Compare LMB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Limbach Holdings Inc.

LMB

Limbach Holdings Inc.

HOLD

Current Price

$78.92

Market Cap

857.4M

ML Signal

HOLD

Logo Collegium Pharmaceutical Inc.

COLL

Collegium Pharmaceutical Inc.

HOLD

Current Price

$49.78

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LMB
COLL
Founded
1901
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Engineering & Construction
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
857.4M
1.5B
IPO Year
2014
2015

Fundamental Metrics

Financial Performance
Metric
LMB
COLL
Price
$78.92
$49.78
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
6
Target Price
$133.50
$47.50
AVG Volume (30 Days)
152.8K
488.1K
Earning Date
11-04-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
39.03
N/A
EPS
3.03
1.63
Revenue
$603,582,000.00
$757,067,000.00
Revenue This Year
$28.00
$26.35
Revenue Next Year
$13.48
$3.67
P/E Ratio
$26.18
$30.66
Revenue Growth
16.56
26.34
52 Week Low
$63.02
$23.23
52 Week High
$154.05
$50.01

Technical Indicators

Market Signals
Indicator
LMB
COLL
Relative Strength Index (RSI) 53.72 70.68
Support Level $78.09 $48.50
Resistance Level $81.97 $49.92
Average True Range (ATR) 3.57 1.30
MACD 0.92 -0.22
Stochastic Oscillator 57.55 93.78

Price Performance

Historical Comparison
LMB
COLL

About LMB Limbach Holdings Inc.

Limbach Holdings Inc is a commercial specialty contractor in the fields of heating, ventilation, air conditioning, plumbing, electrical, and building controls for the design and construction of new and renovated buildings, maintenance services, energy retrofits, and equipment upgrades. It operates in two segments namely General Contractor Relationships (GCR) and Owner Direct Relationships (ODR). The company generates maximum revenue from the ODR segment.

About COLL Collegium Pharmaceutical Inc.

Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Share on Social Networks: